<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05052073</url>
  </required_header>
  <id_info>
    <org_study_id>MyoMet</org_study_id>
    <nct_id>NCT05052073</nct_id>
  </id_info>
  <brief_title>Interaction of Muscle Dystrophy, Glucose Metabolism and Insulin Sensitivity</brief_title>
  <acronym>MyoMet</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this project to characterize systemic and organ-specific (subcutaneous adipose&#xD;
      tissue and skeletal muscle) metabolic responses at rest and during standardized, moderate&#xD;
      exercise after an oral glucose load in patients with various geneticaly heritable foms of&#xD;
      skeletal muscle dystrophies. Metabolic responses will be monitored by indirect calorimetry&#xD;
      (canopy and/or metabolic chamber at rest and during exercise) and microdialysis (adipose&#xD;
      tissue and skeletal muscle at rest) before and after an oral glucose load (75 g).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2009</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>2 Days</target_duration>
  <primary_outcome>
    <measure>muscle dialysate lactate</measure>
    <time_frame>15 minutes intervals after glucose over three hours</time_frame>
    <description>marker for anaerobic glycolysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>muscle dialysate pyruvate</measure>
    <time_frame>15 minutes intervals after glucose over three hours</time_frame>
    <description>marker for aerobic glycolysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>muscle tissue perfusion</measure>
    <time_frame>15 minutes intervals after glucose over three hours</time_frame>
    <description>measured by microdialysis and ethanol dial / ethanol perf ratio (no dimensions)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>energy expenditure</measure>
    <time_frame>15 minutes intervals after glucose over three hours</time_frame>
    <description>measured by indirect calorimetry either at rest (canopy device) or during exercise (metabolic chamber)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Various Forms of Skeletal Muscle Dystrophy</condition>
  <arm_group>
    <arm_group_label>MD patients</arm_group_label>
    <description>patients with different forms of muscle dystrophy, for example&#xD;
facioscapulohumeral dystrophy&#xD;
dysferlinopathy&#xD;
caveolinopathy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>- healthy age- and sex-matched controls (10 men, 10 women)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>oral glucose load at rest</intervention_name>
    <description>oral glucose load (75 g) after an 12h overnight fast at rest accompanied by blood sampling and dialysate sampling (adipose tissue and skeletal muscle), and calorimetry (canopy) over three hours.</description>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>MD patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>oral glucose load and exercise</intervention_name>
    <description>oral glucose load (75 g) after an 12h overnight fast followed by a defined (0.5 W / kg), moderate bicycle exercise i a metabolic chamber</description>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>MD patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  blood sample&#xD;
&#xD;
        -  adipose tissue dialysate samples (microdialysis)&#xD;
&#xD;
        -  skeletal muscle dialysate samples (microdialysis)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        -  out-patient clinic at Charité Universitätsmedizin Berlin, Campus Buch&#xD;
&#xD;
          -  University Campus of Charité Universitätsmedizin Berlin&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  controls: healthy, no metabolic, endocrine, neurologic or other diseases&#xD;
&#xD;
          -  patients: genetically confirmed diagnosis of muscle dystrophy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  known hemorrhagic diseases / coagulopathies&#xD;
&#xD;
          -  intake of oral anti-coagulant drugs (control of PTT, INR and platelet count before&#xD;
             study entry)&#xD;
&#xD;
          -  insulin-dependent Diabetes mellitus&#xD;
&#xD;
          -  pregnancy and lactation period&#xD;
&#xD;
          -  chronic use of non-steroidal antiphlogistics&#xD;
&#xD;
          -  alcohol and drug abuse&#xD;
&#xD;
          -  Claustrophobia • gleichzeitige Teilnahme an einer anderen Studie; Teilnahme an einer&#xD;
             Studie vor weniger als zwei Monaten Unfähigkeit, die mündlichen und schriftlichen&#xD;
             Informationen zur Studie zu verstehen und das schriftliche Einverständnis zu geben&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michael Boschmann, Dr. med.</last_name>
    <phone>+49.30.450.540.241</phone>
    <email>michael.boschmann@charite.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Charite University Medicine, ECRC</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Boschmann, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Michael Boschmann, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 9, 2021</study_first_submitted>
  <study_first_submitted_qc>September 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2021</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Michael Boschmann</investigator_full_name>
    <investigator_title>Dr. med.</investigator_title>
  </responsible_party>
  <keyword>muscle dystrophy</keyword>
  <keyword>energy metabolism</keyword>
  <keyword>calorimetry</keyword>
  <keyword>metabolic chamber</keyword>
  <keyword>microdialysis</keyword>
  <keyword>exercise</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

